The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663
Abstract
Purpose: The mechanisms responsible for prostate cancer androgen independence are diverse. Mutations of the androgen receptor (AR) gene that broaden ligand specificity have been implicated. Bone marrow specimens containing prostate tumor were obtained from men undergoing antiandrogen withdrawal for AR sequence analysis and clinical correlation. Materials and Methods: Eligible men enrolled on a trial of antiandrogen withdrawal had a minimum prostate-specific antigen (PSA) level of 5 ng/dL that was increasing on castration therapy including an antiandrogen. With informed consent, marrow biopsies were obtained to collect prostate tumor. Additional samples were obtained from men enrolled on chemotherapy trials. AR cDNA or DNA was polymerase chain reaction–amplified, cloned, and sequenced. The AR CAG repeat length was recorded. Results: One hundred eighty-four bone marrow biopsies were obtained, and 48 had prostate tumor detected by light microscopy. The ARs from these 48 samples were sequenced. Overall, five (10%) of 48 tumors had mutated ARs. AR point mutations were detected in the hormone-binding domain involved in transcription factor binding. Three mutations were novel in prostate cancer. One tumor sample had a CAG repeat length of 21, compared with germline length of 22 repeats. There was no association between detectability of AR mutations and antiandrogen withdrawal response or survival. Conclusion: These data suggest that AR mutations are present in approximately 10% of patients with prostate cancer who experience treatment failure with hormone therapy that included an antiandrogen. Mutations in the AR likely confer a growth advantage for a subset of progressive prostate cancers. Correlation of AR mutation with antiandrogen withdrawal response or survival could not be made.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Self-citationVeldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Koivisto, P. A., Kononen, J., Palmberg, C., Tammela, T. L. J., HYYTINEN, E.-R., Isola, J. J., Trapman, J., Cleutjens, K. B. J. M., Noordzij, M. A., Visakorpi, T., et al. (1997) · PubMed · Cited by 728
Activation of Programmed Cell Death in the Rat Ventral Prostate after Castration*
KYPRIANOU, N., & ISAACS, J. T. (1988) · Endocrinology · doi:10.1210/endo-122-2-552 · Cited by 720
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 596
Self-citationZhao, X.-Y., Malloy, P. J., Krishnan, A. V., Swami, S., Navone, N. M., Peehl, D. M., & Feldman, D. (2000) · Nature Medicine · doi:10.1038/76287 · Cited by 536
Culig, Z. (1993) · Molecular Endocrinology · doi:10.1210/me.7.12.1541 · Cited by 440
Androgen receptor gene mutations in human prostate cancer.
Newmark, J. R., Hardy, D. O., Tonb, D. C., Carter, B. S., Epstein, J. I., Isaacs, W. B., Brown, T. R., & Barrack, E. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6319 · Cited by 419
Triplet repeat mutations in human disease
Caskey, C., Pizzuti, A., Fu, Y., Fenwick, R., & Nelson, D. (1992) · Science · doi:10.1126/science.1589758 · Cited by 417
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher, H. I., & Kelly, W. K. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1566 · Cited by 405
Tilley, W. D., Buchanan, G., Hickey, T. E., & Bentel, J. M. (1996) · PubMed · Cited by 396
The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit.
Güssow, D., Rein, R., Ginjaar, I., Hochstenbach, F., Seemann, G., Kottman, A., & Ploegh, H. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.9.3132 · Cited by 319
Androgen receptor expression in human tissues: an immunohistochemical study.
Ruizeveld de Winter, J. A., Trapman, J., Vermey, M., Mulder, E., Zegers, N. D., & van der Kwast, T. H. (1991) · Journal of Histochemistry & Cytochemistry · doi:10.1177/39.7.1865110 · Cited by 314
Androgen receptor mutations in prostate cancer.
Barrack, E. R. (1996) · PubMed · Cited by 300
The androgen receptor gene mutations database
Gottlieb, B. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.151 · Cited by 268
Androgen receptor gene mutations in human prostate cancer
Suzuki, H., Sato, N., Watabe, Y., Masai, M., Seino, S., & Shimazaki, J. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90316-o · Cited by 226
Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Fenton, M. A., Shuster, T. D., Fertig, A., Taplin, M. E., Kolvenbag, G. J. C. M., Bubley, G. J., & Balk, S. P. (1997) · PubMed · Cited by 225
Self-citationBerrevoets, C. A. (1998) · Molecular Endocrinology · doi:10.1210/me.12.8.1172 · Cited by 212
Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.
Small, E. J., & Vogelzang, N. J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.382 · Cited by 207
Self-citationHIGH DOSE BICALUTAMIDE FOR ANDROGEN INDEPENDENT PROSTATE CANCER: EFFECT OF PRIOR HORMONAL THERAPY
Joyce, R., Fenton, M. A., Rode, P., Constantine, M., Gaynes, L., Kolvenbag, G., DeWolf, W., Balk, S., Taplin, M. E., & Bubley, G. J. (1998) · Journal of Urology · doi:10.1016/s0022-5347(01)64039-4 · Cited by 205
Self-citationCollocation of androgen receptor gene mutations in prostate cancer.
Buchanan, G., Greenberg, N. M., Scher, H. I., Harris, J. M., Marshall, V. R., & Tilley, W. D. (2001) · PubMed · Cited by 181
Microsatellite Mutation (Cag24→18) in the Androgen Receptor Gene in Human Prostate Cancer
Schoenberg, M. P., Hakimi, J. M., Wang, S. P., Bova, G. S., Epstein, J. I., Fischbeck, K. H., Isaacs, W. B., Walsh, P. C., & Barrack, E. R. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1011 · Cited by 166
The Androgen Receptor Gene Mutations Database
Gottlieb, B. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.234 · Cited by 135
Androgen receptor gene mutations in hormone-refractory prostate cancer
Wall�n, M., Linja, M. J., Kaartinen, K., Schleutker, J., & Visakorpi, T. (1999) · The Journal of Pathology · Cited by 115
Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men.
Takahashi, H., Furusato, M., Allsbrook, W. C., Nishii, H., Wakui, S., Barrett, J. C., & Boyd, J. A. (1995) · PubMed · Cited by 91
Human Androgen Receptor Expression in Prostate Cancer following Androgen Ablation
White, R. D., Meyers, F. J., Chi, S.-G., Chamberlain, S., Siders, D. B., Lee, F., STEWART, S. L., & Gumerlock, P. H. (1997) · European Urology · doi:10.1159/000474409 · Cited by 70
STEROID HORMONE WITHDRAWAL SYNDROMES
Kelly, W. K., Slovin, S. F., & Scher, H. I. (1997) · Urologic Clinics of North America · doi:10.1016/s0094-0143(05)70389-x · Cited by 68
Cited by
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Metadata
- Authors
- Taplin, M.-E., Rajeshkumar, B., Halabi, S., Werner, C. P., Woda, B. A., Picus, J., Stadler, W., Hayes, D. F., Kantoff, P. W., Vogelzang, N. J., & Small, E. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-07-15
- Volume
- 21
- Issue
- 14
- Pages
- 2673-2678
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2118906905
- Cited by
- 364
- References
- 30
- FWCI
- 14.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.